Objective. Breast cancer patients are at an increased risk of osteoporosis due to age, cancer, chemotherapy, and aromatase inhibitor therapy. This retrospective review determined if patients treated with aromatase inhibitors received appropriate screening and management for osteoporosis.
Design. University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied. Data was collected for each patient from the time of breast cancer diagnosis up to April 2007. The study endpoints included (1) appropriate screening for osteoporosis, (2) incidence of osteoporosis diagnosis, and (3) initiation of appropriate drug therapy for bone loss. Appropriate management was defined as adherence to the 2003 American Society of Clinical Oncology guidelines for bone health issues in women with breast cancer.
Results. Of the 54 patients included in this study, 12 (22.2%) had no DEXA scans documented, 22 (40.7%) patients received a baseline DEXA scan and 8 (14.8%) patients received baseline and yearly DEXA scans. During the study timeline, 26 (48%) patients were diagnosed with osteopenia and 4 (7%) patients were diagnosed with osteoporosis. Forty-one (75.9%) patients received calcium and vitamin D therapy. Bisphosphonate therapy was received by less than one-third of the osteopenic patients and three-fourths of the osteoporotic patients.
Conclusions. The majority of patients were not adequately screened which may have falsely lowered the diagnosis of osteoporosis resulting in omission of drug therapy. All high-risk patients should receive calcium and vitamin D therapy and be evaluated for bisphosphonate therapy. Screening and medical management for osteoporosis in breast cancer patients on aromatase inhibitors is an important area for clinical intervention. J Oncol Pharm Practice (2008) 14: 139—145.
Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK eds. SEER cancer statistics review, 1975-2004 , National Cancer Institute, Bethesda, MD.
2.
Brunner LC, Eshilian-Oates L., Kuo TYHip fractures in adults. Am Fam Physician2003; 67: 537-42.
3.
Baum M., Buzdar AU, Cuzick J. et al. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet2002; 359: 2131-9.
4.
Goss PE, Ingle JN, Martino S. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003; 349: 1793-802.
5.
Boccardo F., Rubagotti A., Amoroso D. et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian Cooperative Study. J Clin Oncol2001; 19: 4209-15.
6.
Coombes RC, Hall E., Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004; 350: 1081-92.
7.
Michaud LBAdjuvant use of aromatase inhibitors in postmenopausal women with breast cancer . Am J Health-Syst Pharm2005; 62: 266-73.
8.
Winer EP, Hudis C., Burstein HJ et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol2005; 23: 619-29.
9.
Invasive Breast Cancer. Practice Guidelines in Oncology - v.2 .2006. National Comprehensive Cancer Network, Inc.2005.
10.
Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a comparison study to NCIC CTG MA.17. J Clin Oncol2006; 24: 3629-35.
11.
Eastell R., Hannon RA, Cuzick J. et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trail. J Bone Miner Res2006; 21: 1215-23.
12.
Mincey BA, Duh MS, Thomas SK et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer2006; 7: 127-32.
13.
Hillner BE, Ingle JN, Chlebowski RT et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health in women with breast cancer. J Clin Oncol2003; 21: 4042-57.
14.
Gnant MF, Mlineritsch B., Luschin-Ebengreuth G. et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian breast and colorectal cancer study group. J Clin Oncol2007; 25: 820-28.
15.
Brufsky A., Harker GW, Beck T. et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol2007; 25: 829-36.
